ANNUAL REPORT 2005-2006
Your Company has, over the years, been known for its trend setting
standards in the Indian pharmaceutical market. All along it has offered
innovative dosage forms at affordable prices, especially in the segments of
ophthalmics, pediatrics, infant diarrhoea, lactose intolerance, and
dermatologicals. Moreover, in the last 5 years, its anti-infective range of
Cephalosporin dosage forms have achieved prominent ORG rankings by gaining
substantial market share and brand equity in record time.
Being the first Indian Company to get the U.K. MHRA approval to manufacture
sterile ophthalmic dosage forms in India, FDC has garnered significant
market share in the U.K., for its ophthalmic range anti-infectives, anti-
glaucoma, and viscolizers. Soon your Company will get regulatory clearances
for a few more ophthalmic products in the U.K., including an anti-allergic
and a new anti-glaucoma dosage form. Similar marketing authorizations are
expected, and will result in meaningful revenues from other countries in
the European Union.
With the approval of the ANVISA (Brazilian Regulatory Authority), our
ophthalmic facility at Waluj will shortly begin to supply ophthalmics to
the Brazilian market with a long-term objective to cater to many more Latin
American countries. In addition, our launch of ophthalmics in the U.S. is
in its final stage. With six ANDA's near approval, we are exploring
marketing options in the U.S.
With the Patent regime in place, you will be pleased to note that your
Company has collaborated with renowned ophthalmologists to develop a novel
single-dose unit (UNIMS), which was launched in India in June 2006. Apart
from patenting and marketing this product in India, this product will soon
be marketed worldwide, after we comply with the Regulatory requirements of
As a progressive Company, FDC is making efforts to develop New Chemical
Entities (NCE's). As a result, a number of new structures in the field of
anti-fungals are at various stages of evaluation. Few of these structures
will be patentable as well as valuable. Moreover, we have developed in-
house capabilities to perform studies on the anti-bacterial activities of
Our new State-of-the-art facility to manufacture Cephalosporin dosage forms
at Baddi, Himachal Pradesh, will commence operations in July 2006. This
facility is built on a global scale, and is geared to meet international
Your Company's biotechnology R&D scientists have developed, in-house,
various mammalian cell lines, which will help us to screen new molecules in
the field of ophthalmology, further strengthening our research
By leveraging the following strengths:
1. Well established brands in several segments.
2. Many leading brands in the ORS, Ophthalmic, and anti-infective segments.
3. World-class, state-of-the-art manufacturing facilities.
4. Regulatory expertise to consistently meet with the standards of the most
stringent regulatory bodies U.S. FDA, U.K. MKHRA, SA MCC, ANVISA, etc.
5. Cost-effective and innovative products.
6. Cutting-edge R&D infrastructure.
We expect to grow steadily in the year 2006-2007.
I take this opportunity to thank you all our shareowners, the medical
fraternity, the consumers, our suppliers, our valuable employees and the
public at large. Thank you for your support, trust and confidence in us -
year after year!
MOHAN A. CHANDAVARKAR
June 24, 2006 Chairman and Managing Director